Clearance of serum HBsAg and anti-HBs seroconversion following antiviral therapy for chronic hepatitis B

Journal of Medical Virology

Volumn 81, Issue 8, 2009, Pages 1336-1342

  Borgniet, Olivier ^a,b   Parvaz, Parviz ^a,c   Bouix, Cécile ^a,b   Chevallier, Philippe ^a,c,d   Trépo, Christian ^a,b,d   André, Patrice ^c,d   Zoulim, Fabien ^a,b,d  

^a INSERM   (France)

^b HÔTEL DIEU   (France)

^c CROIX ROUSSE HOSPITAL   (France)

^d UNIVERSITÉ LYON 1   (France)

Author keywords

Hepatitis B virus; Serological assay; Treatment monitoring

Indexed keywords

ACICLOVIR; ADEFOVIR; ALPHA INTERFERON; BETA INTERFERON; ENTECAVIR; FAMCICLOVIR; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; INTERFERON; LAMIVUDINE; NUCLEOSIDE ANALOG; PEGINTERFERON; VIRUS DNA;

ADULT; AGED; ANTIGEN DETECTION; ANTIVIRAL THERAPY; ARTICLE; BIOASSAY; CLINICAL ARTICLE; DRUG DOSE REDUCTION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HEPATITIS B; HUMAN; KINETICS; LIVER CELL; MALE; QUANTITATIVE ANALYSIS; SEROCONVERSION; VIREMIA;

ADULT; AGED; ANTIVIRAL AGENTS; DNA, VIRAL; DRUG MONITORING; FEMALE; HEPATITIS B ANTIBODIES; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B, CHRONIC; HUMANS; MALE; MIDDLE AGED; TREATMENT OUTCOME;

HEPATITIS B VIRUS;

EID: 68049090944     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.21519     Document Type: Article

References (25)

1. AhnSH, Park YN, Park JY, Chang HY, Lee JM, Shin JE,HanKH, Park C, Moon YM, Chon CY. 2005. Long-term clinical and histological outcomes in patients with spontaneous hepatitis B surface antigen seroclearance. J Hepatol 42:188-194. (Pubitemid 40143464)
2. Brunetto MR, Moriconi F, Bonino F, Lau GK, Farci P, Yurdaydin C, Piratvisuth T, Luo K, Wang Y, Hadziyannis S, Wolf E, McCloud P, Batria R, Marcelin P. 2009.HepatitisBvirus surface antigen levels: A guide to sustained response to peginterferon alfa-2a in HBeAgnegative chronic hepatitis B. Hepatology 49:1141-1150.
3. Flink HJ, van Zonneveld M, Hansen BE, de Man RA, Schalm SW, Janssen HL. 2006. Treatment with Peg-interferon alpha-2b for HBeAg-positive chronic hepatitis B: HBsAg loss is associated with HBV genotype. Am J Gastroenterol 101:297-303. (Pubitemid 43381671)
4. Kohmoto M, Enomoto M, Tamori A, Habu D, Takeda T, Kawada N, Sakaguchi H, Seki S, Shiomi S, Nishiguchi S. 2005. Quantitative detection of hepatitis B surface antigen by chemiluminescent microparticle immunoassay during lamivudine treatment of chronic hepatitis B virus carriers. J Med Virol 75:235-239. (Pubitemid 40053734)
5. Lai CL, Shouval D, Lok AS, Chang TT, Cheinquer H, Goodman Z, DeHertoghD,Wilber R, Zink RC, Cross A, Colonno R, Fernandes L. 2006. Entecavir versus lamivudine for patients with HBeAgnegative chronic hepatitis B. N Engl J Med 354:1011-1020. (Pubitemid 43357805)
6. Lok AS, McMahon BJ. 2007. Chronic hepatitis B. Hepatology 45:507-539.
7. Lok AS, Zoulim F, Locarnini S, Bartholomeusz A, Ghany MG, Pawlotsky JM, Liaw YF, Mizokami M, Kuiken C. 2007. Antiviral drug-resistant HBV: Standardization of nomenclature and assays and recommendations for management. Hepatology 46:254-265. (Pubitemid 47171942)
8. Lutgehetmann M, Volzt T, Quaas A, Zankel M, Fischer C, Dandri M, Petersen J. 2008. Sequential combination therapy leads to biochemical and histological improvement despite low ongoing intrahepatic hepatitis B virus replication. Antivir Ther 13:57-66. (Pubitemid 351541674)
9. Maynard M, Parvaz P, Durantel S, Chevallier M, Chevallier P, Lot M, Trepo C, Zoulim F. 2005. Sustained HBs seroconversion during lamivudine and adefovir dipivoxil combination therapy for lamivudine failure. J Hepatol 42:279-281. (Pubitemid 40143478)
10. Moucari R, Mackiewicz V, Lada O, Ripault MP, Castelnau C, Martinot-Peignoux M, Dauvergne A, Asselah T, Boyer N, Bedossa P, Valla D, Vidaud M, Nicolas-Chanoine MH, Marcelin P. 2009. Early serum HBsAg drop: A strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients. Hepatology 49:1151-1157.
11. Muhlbacher A, Weber B, Burgisser P, Eiras A, Cabrera J, Louisirirotchanakul S, Tiller FW, Kim HS, Helden JV, Bossi V, Echevarria JM. 2008. Multicenter study of a new fully automated HBsAg screening assay with enhanced sensitivity for the detection of HBV mutants. Med Microbiol Immunol 197:55-64. (Pubitemid 350161754)
12. Ozaras R, Tabak F, Tahan V, Ozturk R, Akin H, Mert A, Senturk H. 2008. Correlation of quantitative assay of HBsAg and HBV DNA levels during chronic HBV treatment. Dig Dis Sci 53:2995-2998.
13. Peters MG, Andersen J, Lynch P, Liu T, Alston-Smith B, Brosgart CL, Jacobson JM, Johnson VA, Pollard RB, Rooney JF, Sherman KE, Swindells S, Polsky B. 2006. Randomized controlled study of tenofovir and adefovir in chronic hepatitis B virus and HIV infection: ACTG A5127. Hepatology 44:1110-1116. (Pubitemid 44748362)
14. Pichoud C, Berby F, Stuyver L, Petit MA, Trepo C, Zoulim F. 2000. Persistence of viral replication after anti-HBe seroconversion during antiviral therapy for chronic hepatitis B. J Hepatol 32:307-316. (Pubitemid 30093911)
15. Pollicino T, Squadrito G, Cerenzia G, Cacciola I, Raffa G, Crax A, Farinati F, Missale G, Smedile A, Tiribelli C, Villa E, Raimondo G. 2004. Hepatitis B virus maintains its pro-oncogenic properties in the case of occult HBV infection. Gastroenterology 126:102-110. (Pubitemid 38040728)
16. Reesink HW, Engelfriet CP, Henn G, Mayr WR, Delage G, Bernier F, Krusius T, Assal A, Gallian P, Corbi C,Morel P, David B, De Micco P, Murokawa H, Yugi H,Hino S, Tadokoro K, Flesland O, Brojer E, LetowskaM,Olim G, Nascimento F, Goncalves H, Castro L, Morais M, Stezinar SL, Alvarez M, Sauleda S,Gonzalez R, Niederhauser C, Stolz M, Allain JP, Owusu-Ofori S, Eglin R, Stramer S, Busch M, Strong DM, Epstein J, Biswas R. 2008. Occult hepatitis B infection in blood donors. Vox Sang 94:153-166.
17. Tran N, Berne R, Chann R, Gauthier M, Martin D, Armand MA,Ollivet A, Teo CG, Ijaz S, Flichman D, Brunetto M, Bielawski KP, Pichoud C, Zoulim F, Vernet G. 2006. European multicenter evaluation of high-density DNA probe arrays for detection of hepatitis B virus resistance mutations and identification of genotypes. J Clin Microbiol 44:2792-2800. (Pubitemid 44228573)
18. Werle-Lapostolle B, Bowden S, Locarnini S, Wursthorn K, Petersen J, Lau G, Trepo C, Marcellin P, Goodman Z, Delaney WET, Xiong S, Brosgart CL, Chen SS, Gibbs CS, Zoulim F. 2004. Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology 126:1750-1758. (Pubitemid 38736340)
19. Wiegand J, Wedemeyer H, Finger A, Heidrich B, Rosenau J, Michel G, Bock CT, Manns MP, Tillmann HL. 2008. A decline in hepatitis B virus surface antigen (hbsag) predicts clearance, but does not correlate with quantitative hbeag or HBV DNA levels. Antivir Ther 13:547-554. (Pubitemid 352016717)
20. Wursthorn K, Buggisch P, Lutgehetmann M, Zollner B, Petersen J. 2006a. Temporary HBV resolution in an HIV-coinfected patient during HBV-directed combination therapy followed by relapse of HBV. Antivir Ther 11:647-652. (Pubitemid 44277431)
21. Wursthorn K, Lutgehetmann M, DandriM,Volz T, Buggisch P, Zollner B, Longerich T, Schirmacher P, Metzler F, Zankel M, Fischer C, Currie G, Brosgart C, Petersen J. 2006b. Peginterferon alpha-2b plus adefovir induce strong cccDNA decline andHBsAgreduction in patients with chronic hepatitis B. Hepatology 44:675-684. (Pubitemid 44433724)
22. Yuen MF, Wong DK, Yuan HJ, Sum SM, Lai CL. 2004. HBsAg seroclearance in Chinese patients receiving lamivudine therapy for chronic hepatitis B virus infection. J Clin Microbiol 42:4882-4884.
23. Yuen MF, Wong DK, Fung J, Ip P, But D, Hung I, Lau K, Yuen JC, Lai CL. 2008. HBsAg seroclearance in chronic hepatitis B in Asian patients: Replicative level and risk of hepatocellular carcinoma. Gastroenterology 135:1192-1199.
24. Zoulim F. 2004. Mechanism of viral persistence and resistance to nucleoside and nucleotide analogs in chronic hepatitis B virus infection. Antiviral Res 64:1-15. (Pubitemid 39307089)
25. Zoulim F, Mimms L, Floreani M, Pichoud C, Chemin I,Kay A, Vitvitski L, TrepoC. 1992.New assays for quantitative determinationof viral markers in management of chronic hepatitis B virus infection. J Clin Microbiol 30:1111-1119.